Logo

Roche's Tecentriq (atezolizumab) + Abraxane Receives CHMP's Recommendation for its Approval in Europe

Share this

Roche's Tecentriq (atezolizumab) + Abraxane Receives CHMP's Recommendation for its Approval in Europe

Shots:

  • The CHMP recommendation is based on P-III IMpassion130 study results assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with 902 patients in ratio (1:1) with unresectable LA or m-TNBC with no prior treatment for m-breast cancer
  • The P-III Impassion130 results: m-PFS (7.5 vs 5.0 mos.); OS in PD-L1-positive population (25.0 vs 18.0 mos.); OS in IIT population (21.0 vs 18.7 mos.)
  • Tecentriq is a mAb targeting PD-L1- blocking its interaction with PD-1 and B7.1 receptor- thus enabling the interaction of T-cells and is an approved therapy in the US & EU as monothx. or combination therapy for NSCLC- SCLC- m-UC and PD-L1+ triple-negative breast cancer

Click here to read full press release/ article

Ref: Roche | Image: Roche


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions